Surrozen Inc
SRZNW0.022USD
+0.006+38.27%
Handelsschluss 04/24, 16:00（ET）Kurse um 15 Minuten verzögert
0.00Marktkapitalisierung
--KGV TTM
mehr Informationen über Surrozen Inc Unternehmen
Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.
Unternehmensinformationen
Unternehmens-codeSRZNW
Name des UnternehmensSurrozen Inc
IPO-datumNov 23, 2020
Gegründet am2021
CEOMr. Craig C. Parker
Anzahl der mitarbeiter- -
WertpapierartCompany Warrant
Geschäftsjahresende- -
Addresse171 Oyster Point Blvd
StadtSOUTH SAN FRANCISCO
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl94080
Telefon16504752820
Websitehttps://www.surrozen.com
Unternehmens-codeSRZNW
IPO-datumNov 23, 2020
Gegründet am2021
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Financial Officer, Chief Operating Officer, Company Secretary
Chief Financial Officer, Chief Operating Officer, Company Secretary
--
--
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
--
--
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Anna Berkenblit, M.D.
Dr. Anna Berkenblit, M.D.
Independent Director
Independent Director
--
--
Mr. Craig C. Parker
Mr. Craig C. Parker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Yang Li, Ph.D.
Mr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
--
--
Dr. Mary Haak-Frendscho, Ph.D.
Dr. Mary Haak-Frendscho, Ph.D.
Independent Director
Independent Director
--
--
Dr. David J. Woodhouse, Ph.D.
Dr. David J. Woodhouse, Ph.D.
Non-Executive Chairman of the Board, Independent Director
Non-Executive Chairman of the Board, Independent Director
--
--
Mr. Christopher Y. Chai
Mr. Christopher Y. Chai
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Financial Officer, Chief Operating Officer, Company Secretary
Chief Financial Officer, Chief Operating Officer, Company Secretary
--
--
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
--
--
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Anna Berkenblit, M.D.
Dr. Anna Berkenblit, M.D.
Independent Director
Independent Director
--
--
Mr. Craig C. Parker
Mr. Craig C. Parker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Yang Li, Ph.D.
Mr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: Fri, Feb 28
Update-Zeit: Fri, Feb 28
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Other
100.00%
Aktionärsstatistik
Aktionäre
Anteil
Other
100.00%
Art
Aktionäre
Anteil
Other
100.00%
Institutionelle Beteiligung
Update-Zeit: Tue, Mar 4
Update-Zeit: Tue, Mar 4
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
28
2.89M
0.00%
-639.43K
2024Q4
28
2.89M
0.00%
-639.43K
2024Q3
30
2.68M
0.00%
-1.42M
2024Q2
29
4.64M
0.00%
-229.29K
2024Q1
27
4.54M
0.00%
-721.56K
2023Q4
27
4.59M
0.00%
-580.20K
2023Q3
24
5.00M
0.00%
-35.88K
2023Q2
22
4.87M
0.00%
-224.97K
2023Q1
23
4.88M
0.00%
-106.68K
2022Q4
23
4.77M
0.00%
-375.46K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Boxer Capital Management, LLC
66.67K
0%
--
--
Dec 31, 2024
Baker Bros. Advisors LP
833.33K
0%
--
--
Dec 31, 2024
LMR Partners LLP
648.28K
0%
+648.28K
--
Dec 31, 2024
Bridger Management, LLC
466.67K
0%
--
--
Dec 31, 2024
Euclidean Capital, L.L.C.
170.83K
0%
--
--
Dec 31, 2024
Perceptive Advisors LLC
166.67K
0%
--
--
Dec 31, 2024
Deerfield Management Company, L.P.
166.67K
0%
--
--
Dec 31, 2024
Samsara BioCapital, LLC
100.00K
0%
--
--
Dec 31, 2024
Cantor Fitzgerald, L.P
70.82K
0%
+35.62K
+101.20%
Dec 31, 2024
EcoR1 Capital, LLC
66.67K
0%
--
--
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten